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ABSTRACT 
1,3-Thiazolylidenehydrazinylidene ethylpyridinium bromide monohydrate, 1,3-thiazolylidenehydrazinium bromide and 1,3-
thiazolylidenehydrazine derivatives were synthesized by heterocyclization of 2-(1-substituted 
ethylidene)hydrazinecarbothioamides, characterized and screened for their anti-bacterial activities. 3h showed the highest 
inhibitory effect against all types of bacterial compared to Moxifloxacin. The structures of synthesized compounds were 
established by spectroscopic (IR, 
1
H, 
13
C-NMR, Mass) and X-ray analyses. 
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INTRODUCTION  
Compounds possessing Schiff bases are well known for their pharmacological properties as antifungal, anti -cancer and 
anti-viral agents [1,2].  
Thiosemicarbazones reacted with cyclization reagents such as dichloroacetone, ethylchloroacetate, ethyl -1,2-
chloroacetoacetate and 2-bromoacetophenone to give substituted (benzylidenehydrazono)thiazoles [3-6]. 
A NBS-mediated sequential one-pot synthesis of multi-functionalized thiazoles from 1,3-dicarbonyl compounds and 
mercaptonitrile salts has been developed under mild conditions [7]. 
The occurrence of thiazole ring system in numerous biologically active molecules have recognized and possess wide 
ranges of biological properties such as antioxidant [8], antibacterial drugs [9 -11], fungicidal treatment [3,12], anti-
inflammatory [13-16], anticonvulsant [17], and anti-HIV [18-20]. 2-Aminothiazole was used as inhibitors of human cancer 
and Alzheimer’s disease [21-24].  
The most frequently used synthetic method of generating thiazoles is the Hantzsch process [25], in which α-haloketone is 
condensed with thioamides. Several methods for the synthesis of tri - substituted thiazoles have been reported [26-29]. 
N-substituted pyridinium salts are widly used in organic synthesis [30-32], and have much attention in the field of non-
linear optics (NLO) [30,31,33] as well as antibacterial and antifungal activities [34]. 
In view of these, it was thought of interest to combine both pharmacophoric moieties 1,3 -thiazole and aromatic compounds 
(with donating and withdrawing groups) as well as heterocyclic ring (such as pyridine). 
A series of substituted 1,3-thiazole derivatives were synthesized and evaluated for their antibacterial activity.    
RESULTS AND DISCUSSION 
Our investigation was performed by reacting 2-(1-substituted-ethylidenehydrazinecarbothioamides 1a-h with 1-aryl-2-
bromoethanones 2a,b in refluxing ethanol/ piperidine, the general synthetic pathway was depicted in (Scheme 1). [(3,4 -
Diaryl-1,3-thiazolylidene)(hydrazineylid-ene)]ethyl-pyridinium bromide monohydrates (3a,b), (3,4-diaryl-1,3-
thiazolylidene)ethylidenehydrazinium bromides (3c,d) and (3,4-diaryl-1,3-thiazolylidene)hydrazines (3e-h) were obtained 
in (80-89%) yields as three different types of thiazole products from the reaction of 1a-h with 2a,b. 
A detailed interpretation of IR bands of 3a is discussed. The IR spectrum of 3a shows a broad band at 3361cm
-1
 which 
can be attributed to NH. The (N-N) stretching band in thiazole derivative 3a observed at 1567 cm
-1
. The IR of 3a revealed 
strong band at 1619 cm
-1
 due to (C=N), the (C-S-C) band was observed at 767 cm
-1
 [6]. A broad band at 3448 due to the 
OH of H2O molecule. 
The 
1
H NMR of 3a chosen as prototype showed that the pyridine-nitrogen still had a proton and pyr-NH resonance at 9.17 
ppm, four proton multiplets at 8.20-8.28 due to pyridine-CH, two singlets at 2.32 and 6.42 because the proton of CH3 and 
thiazole-CH, respectively. A broad signal at 1.6 ppm due to OH of one molecule of H2O. Multiplets at 7.12-7.78 accounting 
for ten aromatic protons. 
 The 
13
C NMR spectrum of 3a supported the 
1
H NMR spectroscopic data by the distinctive appearance of carbon signals 
representing acyclic C=N at δH=157.22 ppm, thiazole C2, C4 resonate at 168.12 and 148.55 ppm, respectively and 
thiazole-CH at 104.06. Furthermore, in the 
13
C NMR of 3a,b, the pyridine-C2 is downfield shifted 148.55-147.12. The 
mass spectrometry fragmentation of 3a was studied under electron ionization. Loss of (HBr+H2 O) giving rise to the ion 
m/z = 363. The resulting fragment ions undergo loss of 104 a.m.u. [C6H5-C(CH3)], and 135 a.m.u. (Ph-N=C=S). 
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Scheme 1 
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The molecular structure of 3a was established by single crystal X-ray analysis (Fig. 1) [35]. The dihedral angle between 
S1/N1C1-C3 thiazolylidene and N4/C18-C22 pyridinium rings is 14.73 C(3)o while that between the phenyl groups C4-C9 
and C10-C15 and the mean plane of the thiazolylidene ring are 34.69 (13) and 64.27 (13)
0
, respectively.  
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Fig. 1. Molecular conformation of 3a with 50% probability displacement eliposids 
 
In the crystal zigzag chains of alternating bromide ions and water molecules associated through O-H…..Br interactions run 
in channels approximately parallel to the b axis [35]. 
On the other hand, 2-((1E)-1-{2-[(2E)-4-(4-bromo-phenyl)-3-phenyl-2,3-dihydro-1,3-thiazol-2-ylidene]hydr-azine-1-
ylidene}ethyl)-pyridinium bromide monohydrate formed during the reaction of 1b with 2b. In the crystal structure of the title 
hydrated salt C22H18BrN4S+.Br-.H2O the N4/C18-C22, C1-C6 and C10-C15 aromatic rings make dihedral angles of 14.20 
(12), 34.29 (10) and 68.75 (11)
0
, respectively with the (S1/N1/C7-C9) thiazole ring (Fig. 2) [36]. 
 
Fig. 2. The crystal structure of the hydrated salt C22H18BrN4S+.Br-.H2O (3b). 
.  
 
The elemental analyses and mass spectra of 3c,d clearly revealed that the products were formed by the addition of one 
molecule of 1c,d to one molecule of 2a,b with elimination one molecule of H2O. The IR spectrum of 3c showed absorption 
of phenolic-OH and NH at 3423 and 3332 cm
-1
, two strong bands at 1612, 1564 due to C=N vibrations and (N-N) 
stretching, respectively. 
The 
1
H NMR spectrum of 3c, two broad signals at 9.51 and 9.20 ppm due to phenolic-OH, and hydrazinium-NH 
respectively. In the 
13
C NMR spectrum of 3c signals at δC= 157.10, 168.53 and 148.79 ppm were assigned to acyclic 
C=N, thiazole-C2 and thiazole-C4, respectively. The following additional remarks are necessary: The 
1
H NMR spectrum of 
3c shows the presence of one sing let at δH= 2.31ppm due to CH3, multiplets at 6.84-7.77 due to aromatic protons. The 
13
C NMR shows the CH3 group at 14.15 and thiazole-CH at 102.83 ppm.  
The single crystal X-ray structure analysis of (Z)-1-[(2E)-3,4-diphenyl-2,3-dihdro-1,3-thiazol-2-ylidene]-2-[1-(4-
hydroxyphenyl)ethylidene]hydrazinium bromide (3c) confirmed that, the dihydrothiazole ring [r.m.s. deviation= 0.015 Å) is 
twisted with respect to each of C- and N-bound phenyl rings and the hydroxy benzene ring, making dihedral angles of 76.0 
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(2), 71.2 (2)  and  9.8 (2)
0
, respectively (Fig. 3) [37]. In the crystal inversion related molecules are linked by association of 
the bromide ions with the cations via N-H….Br and O-H….Br hydrogen-bonding interactions [37]. 
 
Fig. 3. Single crystal x-ray structure of 3c 
 
 
Substitution the p-hydrogen atom of benzene ring attached to thiazole-C4 by bromide afforded the title compound 3d. For 
further elucidation the structure of 3d, the single crystal X-ray diffraction has carried out and showed that the bromo-
phenyl, phenyl and phenol rings make dihedral angles of 46.5 (1), 66.78 (8) and 15.4 (2), respectively, with the mean 
squares plane of the thiazolidene ring. In the crystal, the lattice water molecule is hydrogen bonded to the phenol group 
and makes a weaker O—H···N connection (Fig. 4) [38]. 
 
Fig. 4 Crystal structure of 3d 
 
 
The structures of the third type of the products containing compounds 3e-h were assigned using spectroscopic tools such 
as IR, NMR (
1
H-,
13
C) and mass spectrometry as well as single crystal X-ray analyses. 
The mass spectrometry and elemental analyses confirm the molecular masses and molecular composition of 3e-h, which 
obtained from reacting one molecule of 1e-h and one molecule of 2a,b via loss a molecule of H2O and another of HBr. 
The 
1
H NMR spectra of 3e-h showed the presence of two singlets with the ratio 3:1 at 2.27-2.38 and 6.17-6.21 to CH3 and 
thiazole-CH, respectively, in addition to aromatic protons. The 
1
H NMR of 3e,f clearly indicated the presence of extra CH3 
centered at 2.35-2.58 ppm. The presence of thiazole-CH was also proved by 
13
C-DEPT NMR spectrum, exhibiting positive 
signals at 101.72-103.14 ppm. Signals at 168.51-169.67 and 148.86-149.12 were observed due to thiazole-C2 and 
thiazole-C4. 
In (1Z,2E)-1-(3,4-diphenyl-2,3-dihydro-1,3-thiazol-2-ylidene)-2-(1-p-tolylrthylidene)hydrazine (3e), the thiazole ring makes 
dihedral angles of 52.03 (6), 62.63 (6) and 12.35 (6)
0
, respectively, with two phenyl rings and the benzene ring (Fig. 5) 
[39]. 
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Fig. 5. Molecular structure of 3e 
 
Moreover, in (2E)-4-(4-bromophenyl)-2-((2Z)-(1-(4-methy(phenyl)ethylidene)hydrazinylidene)-3-phenyl-2,3-dihydro-1,3-
thiazole (3f), the dihydrothiazele ring is approximately plannar with a maximum deviation of 0.08 (2) Å, and is twisted with 
respect to the 4-bromophenyl ring, the phenyl ring and methyl phenyl ring, making dihedral angles of 47.96 (8), 59.52 (9) 
and 16.96 (9)
0
, respectively (Fig. 6) [40]. 
 
Fig. 6. Perspective view of 3f showing the planarity of thiazole ring  
 
A rational for the formation of compounds 3a-h as depicted in (Scheme 2) via the formation of intermediate 4a-h followed 
by elimination a molecule of HBr and another of H2O. 
 
Scheme 2 
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Conclusion 
In summary, we have described the synthesis for four types of thiazolylidenhydrazine derivatives via heterocyclization of 
2-(1-substituted ethylidene)hydrazinecarbothio-amides by the reaction with 1-aryl-2-bromoethanones. The first type of 
products is substituted 1,3-thiazolylidene-hydrazonylidene ethylpyridinium bromide monohydrate, whereas substituted 1,3-
thiazolylidenehydrazinium bromide is the second type of products. The third, is the hemihydrate of 1,3 -thiazolylidene 
hydrazine derivatives in addition to the derivatives of 1,3-thiazolylidene hydrazine as the fourth type. Among all types of 
1,3-thiazolylidene hydrazines, 3h showed the highest inhibitory effect against all gram positive and gram negative bacterial 
strains compared to the standard broad spectrum antibiotic Moxifloxacin. 
Experimental 
Melting points were determined using open glass capillaries on a Gallenkamp melting point apparatus (Weiss -
Gallenkamp, loughborough, UK) and are uncorrected. Infrared spectra (υ/cm
-1
) were recorded from potassium bromide 
disks with a Shimadzu 408 (Shimadzu corporation, Kyoto, Japan). 
1
H- and 
13
C-NMR spectra (400 MHz for 
1
H, 100 MHz 
for 
13
C) were observed in CDCl3 on DELTA2-NMR spectrometer (DELTA2, Manchester Metropolitan University, United 
Kingdom) with tetramethylsilane as the internal standard.  The 
13
C-NMR signals were ass igned with the aid of DEPT 
135/90 experiments. Mass spectra (70 eV, electron impact mode) were recorded on Finnegan MAT 312 (Germany) 
instrument. X-ray diffractions were measured using Bruker SMART APEX CCD diffractometer with Graphite 
monochromator and fine-focus scaled tube as a Radiation source. Thin layer chromatography (TLC) was performed on 
analytical Merck 9385 Silica aluminium sheets ( Kieselgel 60) with Pf 254 indicator, TLC’s were viewed at λmax=  254 nm. 
Elemental analyses were carried out at Microanalytical Center, Cairo University, Egypt.  
Starting Materials 
2-(1-Substituted ethylidene)hydrazinecarbothioamides 1a-h were prepared by condensation 4-phenylthiosemicarbazide 
with the appropriate ketones according to the published procedures [41,42]. 1 -Aryl-2-bromoethanones (2a,b) were 
prepared according to Nobuta and Salama [43,44]. Anti-bacterial activity has been carried out at Botany Department, 
Sohag University.  
Products 
Synthesis of 1,3-thiazolylidenehydrazinylidene pyridinium salts and 1,3-
thiazolylidenehydrazine derivatives 3a-h 
General procedure 
A mixture of (1 mmol) 2-(1-substituted ethylidene)hydrazine-carbothioamides  1a-h and (1 mmol) of 1-aryl-2-
bromoethanones (2a,h) in absolute ethanol (30 ml) was refluxed for 6-8 h, then cooled to room temperature. A yellow solid 
precipitated,  it was filtered and washed with a small amount of ethanol and recrystallized from ethanol to afford good 
quality crystals.  
2-((1E)-1-{2-[(2Z)-3 ,4-Diphenyl-2,3-dihydro-1,3-thizol-2-ylidene]hydrazine -1-ylidene}ethyl)pyridin-1-ium 
bromide monohydrate (3a). Yellow crystals (ethanol), m.p 234-236 
o
C (0.38 g, 81%),  IR (KBr)= 3361 (Pyr-
+
NH), 1619 
(C=N), 1567 ( N-N ) stretching . 
1
H-NMR (CDCl3) δH= 1.61 (br, 2H, H2O), 2.32 (s, 3H, CH3), 6.42 (s, 1H, thiazole-CH), 
7.12-7.23 (m, 2H, Ar-H), 7.24-7.26 (m, 4H, Ar-H), 7.28-7.33 (m, 4H, Ar-H), 8.20-8.28 (m, 4H, pyr-H), 9.17 (br, 1H, pyr-
+
NH). 
13
C NMR (CDCl3) δC= 14.17 (CH3), 104.06 (thiazole-CH), 123.24, 123.51, 128.26, 128.39, 128.50, 128.94 (Ar-CH), 
130.41, 130.80 (pyridine-CH), 131.05, 137.08 (Ar-C), 141.20, 141.63 (pyridine-CH), 146.37 (pyridine-C), 148.55 (thiazole-
C4), 157.22 (acyclic C=N), 168.12 (thiazole-C2).  Ms.  m/z  (%) 363 (M
+
-(HBr+H2O), 23), 263 (10), 236 (18), 135 (27), 104 
(76), 77 (100). Anal. Calcd for C22H21BrN4O5 (469.40), C, 56.29; H, 4.51; Br, 17.02; N, 11.94; S, 6.83. Found C, 56.17; H, 
4.61; Br, 16.88; N, 12.11, S, 6.94. 
2-((1E)-1-{2-[(2Z)-4-(4-Bromophenyl)-3-phenyl-2,3-di-hydro-1,3-thiazol-2-ylidene]hydrazin-1-
ylidene}ethyl) pyr idine-1-iumbromide monohydrate (3b). Yellow crystals (ethanol), m.p. 248-250 
o
C (0.47g, 
68%), IR (KBr)= 3346 ( pyr-
+
NH), 1614 (C=N),  1576 (N-N) stretching. 
1
H NMR (CDCl3) δH = 1.63 ( br, 2H, H2O), 2.49 (s, 
3H, CH3), 6.41 (s, 1H, thiazole-CH), 6.97-6.99 (m, 2H, Ar-H), 7.27-7.34 ( m, 4H, Ar-H), 7.36-7.37 ( m, 3H, Ar-H), 8.23-8.25 
(m, 4H, pyr-H), 9.10 (br, 1H, pyr-
+
NH). 
13
C NMR ( CDCl3) δC= 14.12 (CH3), 103.12 (thiazole-CH), 122.82, 123.56, 128.23, 
129.12, 129.92 (Ar-CH), 130.94, 131.27 (pyridine-CH), 128.14, 131.77, 141.03 (Ar-C), 141.63, 141.94 (pyridine-CH), 
147.12 ( Pyridine-C), 149.11 (thiazole-C4), 156.38 (acyclic C=N), 168.51 (thiazole-C2). MS. m/z (%) 466-468 (M
+
-
(HBr+H2O), 15), 343 (16), 315 (28), 135 (43), 105 (81), 77 (100). Anal. Calcd for C 22H20Br2N4OS (548.29), C, 48.19; H, 
3.68; Br, 29.15; N, 10.22; S, 5.85. Found C, 48.33; H, 3.74; Br, 28.96; N, 10.37; S, 5.69.  
(Z)-1-[(2E)-3 ,4-Diphenyl2,3 -dihydro-1,3-thiazol-2-yli-dene]-2-[1-(4-hydroxyphenyl)ethylidene]hydrazinium 
bromide (3c). Yellow crystals (ethanol), mp 260-262 
o
C (0.705 g, 85%), IR (KBr)= 3423 (OH), 3332 (hydrazinium NH
+
), 
1616 (C=N), 1595 (Ar C=C), 1564 (N-N) stretching. 
1
H NMR (CDCl3) δH= 2.31 (s, 3H, CH3), 6.3 (s, 1H, thiazole-CH), 6.84-
6.99 (m, 3H, Ar-H), 7.11-7.18 (m, 3H, Ar-H), 7.20-7.29 (m, 3H, Ar-H), 7.33-7.55 (m, 2H, Ar-H), 7.75-7.77 (m, 2H, Ar-H) 
9.51 (br, 1H, CH), 9.20 (br, 1H, NH). 
13
C NMR (CDCl3) δC= 14.15 (CH3), 101.83 (thiazole-CH), 122.88, 125.26, 125.54, 
126.27, 127.12, 127.88, 128.21 (Ar-CH) 124.16, 131.22, 133.12, 142.14 (Ar-C), 148.79 (thiazole-C4), 157.10 (acyclic 
C=N), 161.05 (Ar-C-CH), 168.53 (thiazole-C2). Ms. m/z (%) 385 (M
+
- HBr, 11), 370 (10), 238 (13), 180 (12), 135 (21), 105 
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(24), 91 (45), 77 (100). Anal. Calcd for C23H20BrN3OS (466.39), C, 59.23; H, 4.32; Br, 17.13; N, 9.01; S, 6.88. Found C, 
59.37, H, 4.21; Br, 16.95; N, 8.87; S, 6.94. 
4-((1E)-1-{(2Z)-2-[4-(4-bromophenyl)-3-phenyl-2,3-dihydro-1,3-thiazol-2-ylidene]hydrazin-1-yl-
idene}ethyl)phenol hemihydrate (3d).  Yellow crystals (ethanol), mp274-276 
o
C (0.454 g, 83%), IR (KBr)                       
(OH),          (hydrazinium, 
+
NH),             (C=N),          (Ar-C=C),              (N-N) stretching. 
1
H NMR (CDCl3) δH= 2.33 (s, 3H, 
CH3), 6.21 (s, 1H, thiazole-CH), 6.81-6.94 (m, 3H, Ar-H), 7.15-7.21 (m, 3H, Ar-H), 7.22-7.30 (m, 3H, Ar-H), 7.45-7.61 (m, 
2H, Ar-H), 7.79-7.82 (m, 2H, Ar-H) 9.63 (br, 1H, CH), 9.28 (br, 1H, NH). 
13
C NMR (CDCl3) δC= 14.43 (CH3), 102.15 
(thiazole-CH), 123.11, 124.76, 125.84, 126.32, 127.10, 127.73, 128.31 (Ar-CH) 124.14, 130.55, 132.87, 141.81 (Ar-C), 
149.19 (thiazole-C4), 158.12 (acyclic C=N), 160.85 (Ar-C-CH), 169.23 (thiazole-C2). 
(1Z,2E)-1-(3,4-Diphenyl-2,3-dihydro-1,3-thiazol-2-yli-dene)-2-(1-p-tolylethylidene)hydrazine (3e).  Yellow 
crystals (ethanol), m.p. 232-234 
o
C (0.31 g, 80%), IR (KBr) = 3060 (Ar-CH), 1629 (C=N), 1594 (Ar-C=C), 1567 (N-N) 
stretching. 
1
H NMR( CDCl3), 2.38 (s, 3H, CH3), 2.58 (S, 3H, CH3), 6.21 (s, 1H, thiazole-CH), 7.08- 7.10 (m, 3H, Ar-H), 
7.17-7.19 (m, 4H, Ar-H), 7.24-7.26 (m, 4H, Ar-H), 7.43-7.45 (m, 3H, Ar-H); 
13
C NMR( CDCl3) δc = 14.31 (CH3), 103.14 
(thiazole-CH), 127.08, 128.11, 128.57, 128.77, 128.94, 129.15, 129.56, 129.79 ( Ar-CH), 130.84, 131.42, 132.16 (Ar-C), 
142.11 (Ar-C-N), 149.11( thiazole-C41, 157.62 (acyclic=N), 168.51 (Thiazole-C2). Ms, m/z (%) 383 (M
+
, 265, 368 (14), 
265 (32), 248 (16), 237 (18), 135 (41), 118 (58), 91 (100), 77 (86). Anal. Calcd for C24H21N3S( 383.51), C, 75.16; H, 5.52; 
N, 10.96; S, 8.36. Found C, 74.47; H, 5.41; N, 11.14; S, 8.51.  
(2E)-4-(4-Bromophenyl)-2-{(2Z)-[1-(4-methylphenyl)-ethylidene]hydrazinylidene}-3-phenyl-2,3-dihydro-
1,3-thiazole (3f) . Yellow crystals (ethanol), m.p. 220-222 
0
C (0.38 g, 83%), IR (KBr)= 3063 (Ar-CH), 1612 (C=N), 1600 
(Ar-C=C), 1564 (N-N) stretching. 
1
H NMR(CDCl3) δH = 2.27 (s, 3H, CH3), 2.35 (s, 3H, CH3), 6.16 ( s, 1H, thiazole-CH), 
6.98-7.00 (m, 2H, Ar-CH), 7.73- 7.76 (m, 3H, Ar-H). 
13
C NMR (CDCl3) δc= 14.84 (CH3), 21.30 (CH3), 102.29 (thiazole-CH), 
126.27, 127.48, 128.25, 128.75, 128.87, 129.51, 129.73 (Ar-H), 124.63, 131.46, 132.16, 132.36, 141.83 (Ar-C), 148.86 
(thiazole-CH), 157.52 (acyclic C=N), 168.52 ( thiazole-C2). MS, m/z (%) 461/463 (M
+
, 21), 381 (16), 135 (20), 118 (93), 41 
(81), 77 (100). Anal. Calcd for C24H2OBrN3OS (462.40) C, 62.34; H, 4.36; Br, 17.28; N, 9.09; S, 6.93. Found C, 62.19; H, 
4.45; Br, 17.41; N, 8.92; S, 7 .11. 
(E)-2-{ (E)-[1-(4-Chlorophenyl)ethylidene]hydrazono} -3,4-diphenyl-2,3-dihydrothiazole (3g) . Yellow crystals 
(ethanol), mp. 176-178 
o
C   (0.36 g,  89%), IR (KBr) = 3048 (Ar-CH),  1603 (C=N), 1590 (Ar-C=C), 1569 (N-N) stretching. 
1
H NMR (CDCl3) δH= 2.30 (s, 3H, CH3), 6.17 (s, 1H, thiazol-CH), 7.11-7.13 (m, 2H, Ar-H), 7.19-7.21 (m, 4H, Ar-H), 7.24-
7.26 (m, 4H, Ar-H), 7.29-7.32 (m, 2H, Ar-H), 7.78-7.80 ( m, 2H, Ar-H). 
13
C NMR (CDCl3) δC= 14.68 (CH3), 101.72 
(thiadiazole-CH), 127.45, 127.59, 128.26, 128.34, 128.39, 128.41, 128.68, 128.83 (Ar-CH), 131.34, 131.89, 132.42, 
141.66 (Ar-C), 149.12 (thiazole-C4), 157.68 (acyclic C=N), 169.67 (thiazole-C2). Ms, m/z (%) 403/405 (M
+
, 26), 388 (14), 
367 (15), 260 (23), 232 (19), 167 (62), 135 (49), 91 (100), 77 (92). Anal. Calcd for C23H18ClN3S (403.93) C, 68.39, H, 4.49, 
Cl, 8.78; S, 7.94. Found C, 68.53; H, 4.37; Cl, 8.62; S, 8.12.  
(E)-4-(4-Bromophenyl)-2-{ (E)-[1-(4-Chlorophenyl)-ethylidene]hydrazono}-3-phenyl-2,3-dihydrothiazol 
(3h). Yellow crystal (ethanol), m.p. 186-188 
o
C (0.392 g, 81%), IR (KBr)=  3076 (Ar-CH), 1605 (C=N), 1585 (Ar-C=C), 
1562 (N-N) stretching. 
1
H NMR (CDCl3) δH= 2.29 (S, 3H, CH3), 6.19 (S, 1H, thiazole-CH), 6.97-6.99 (m, 2H, Ar-H), 7.25-
7.29 (m, 4H, Ar-H), 7.31-7.35 (m, 4H, Ar-H), 7.77-7.81 (m, 3H, Ar-H). 
13
C NMR (CDCl3) δC= 14.59 (CH3), 102.50 (thiazole-
CH), 127.50, 127.55, 128.22, 128.29, 128.76, 129.12, 129.52 (Ar-CH), 130.13, 131.47, 131.76, 132.14, 141.26 (Ar-C), 
149.11 (thiazole-C4), 155.97 (acyclic C=N), 169.26 (thiazole C2) Ms, m/z (%) 481/485 (M
+
, 14), 445/447 (26), 430 (11), 
401 (25), 342 (11), 167 (10), 139 (32), 135 (41), 91 (82), 77 (100). Anal. Calcd for C23H17BrClN3S (482.82) C, 57.21; H, 
3.55; Br, 16.55; Cl, 7.34; N, 8.70; S, 6.64. Found, C, 57.07; H, 3.62; Br, 16.69; Cl, 7.28; N, 8.56; S, 6.76.   
Anti-bacterial Activity 
The synthesized compounds 3a-h were dissolved in DMSO. In order to ensure that the solvent had no effect on bacterial 
growth or enzymatic activity, negative control tests were performed using DMSO at the same concentrations.  
The inhibitory effect of tested compounds 3a-h on the in vitro growth of four different types of bacteria Bacillus cereus and 
Micrococcus lutues as gram positive bacteria (+ve) and Psedomonas aureginosa and Serratia marcescens as gram 
negative bacteria (-ve) was evaluated using agar diffusion method (cup and plate method) [45 -48]. All plates were 
incubated at 37±0.5 ºC for 24 h. The inhibition zone of active compounds was measured in cm scale. The results shown in 
table 1 revealed that compounds 3h and 3f showed the highest inhibitory effect against the two types of bacteria at the 
three used concentrations, while compounds 3d and 3e, showed moderate activity compared to the standard Moxifloxacin 
as a broad spectrum antibiotic. Compound 3h exhibited the highest inhibitory effect against the gram positive Bacillus 
cereus at high concentration while 3c showed high inhibition zone against the gram positive bacteria Micrococcus lutues 
at low concentration. On the other hand, compounds 3a-c, 3e and 3g showed no bactericidal activity against the gram 
negative bacterial Psedomonas aureginosa (table 1). 
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Table 1: Anti-bacterial activity of compounds 3a-h 
                                        
.  
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